Live-attenuated CHIKV vaccine VLA1553

Pre-clinicalRecruiting

0 watching 0 views this week💤 Quiet

Hype Score

Development Stage

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Chikungunya Virus Infection

Conditions

Chikungunya Virus Infection

Trial Timeline

Feb 2, 2026 → Feb 28, 2027

NCT ID

NCT07254702

About Live-attenuated CHIKV vaccine VLA1553

Live-attenuated CHIKV vaccine VLA1553 is a pre-clinical stage product being developed by Valneva SE for Chikungunya Virus Infection. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07254702. Target conditions include Chikungunya Virus Infection.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (3)

NCT ID	Phase	Status	Start	Completion	Indication
NCT07254702	Pre-clinical	Recruiting	Feb 2, 2026	Feb 28, 2027	Chikungunya Virus Infection
NCT07347002	Pre-clinical	Recruiting	Feb 2, 2026	Dec 31, 2027	Chikungunya Virus Infection
NCT07163845	Pre-clinical	Active	Sep 22, 2025	Dec 31, 2026	Chikungunya Virus Infection

Competing Products

20 competing products in Chikungunya Virus Infection

See all competitors

Product	Company	Stage	Hype Score
CHIKV VLP/unadjuvanted + CHIKV VLP/adjuvanted + Placebo	Bavarian Nordic	Phase 2	49
Chikungunya	Bavarian Nordic	Phase 2	49
CHIKV VLP vaccine booster + Placebo booster	Bavarian Nordic	Phase 3	74
CHIKV VLP/adjuvant + Placebo	Bavarian Nordic	Phase 3	74
CHIKV VLP, adjuvanted	Bavarian Nordic	Phase 2	49
CHIKV VLP/adjuvant + Placebo	Bavarian Nordic	Phase 3	74
CHIKV VLP vaccine + Placebo	Bavarian Nordic	Phase 3	74
CHIKV VLP vaccine + Placebo	Bavarian Nordic	Phase 3	74
VLA1553	Valneva SE	Phase 3	72
Live-attenuated CHIKV vaccine VLA1553	Valneva SE	Pre-clinical	18
Biological Vaccine VLA1553	Valneva SE	Phase 3	72
VLA1553 full dose + VLA1553 half dose + Control	Valneva SE	Phase 2	47
Active + Placebo	Valneva SE	Phase 3	72
Live-attenuated CHIKV vaccine VLA1553 + Vaccine(s) approved for use during pregnancy by the MoH	Valneva SE	Pre-clinical	18
VLA1553	Valneva SE	Phase 3	72
VLA1553 + Control	Valneva SE	Phase 3	72
VLA1553 + Placebo	Valneva SE	Phase 3	72
VLA1553	Valneva SE	Phase 1	28
Live-attenuated CHIKV vaccine VLA1553	Valneva SE	Pre-clinical	18
INTERCEPT Platelets	Cerus	Pre-clinical	15

Other Products from Valneva SE

IXIARO®- Japanese Encephalitis vaccineApproved

IXIARO®Approved

Japanese Encephalitis purified inactivated vaccinePhase 3

IC51 + HAVRIXPhase 3

IXIARO + IXIAROPhase 3